Sun Pharmaceutical Industries has announced a strategic licensing agreement with Takeda Pharmaceutical Company to introduce a new gastrointestinal drug in India. The Mumbai-based pharmaceutical company will commercialize Vonoprazan tablets in strengths of 10 mg and 20 mg under a non-exclusive patent license from Takeda.
Vonoprazan is a pioneering oral potassium competitive acid blocker (PCAB) designed to treat reflux esophagitis and other acid peptic disorders effectively.
“We are thrilled to partner with Takeda to bring Vonoprazan to India,” said Kirti Ganorkar, CEO – India Business at Sun Pharma. This collaboration underscores Sun Pharma’s commitment to advancing gastrointestinal health by offering patients and healthcare providers a novel therapeutic option for managing acid peptic disorders.
Approved by the US FDA in November 2023, Vonoprazan is recognized for its efficacy in healing and maintaining all grades of erosive esophagitis and alleviating heartburn associated with the condition. It is also approved for treating Helicobacter pylori (H. pylori) infection in adults, either in combination with antibiotics or alone.
Takeda, the developer of Vonoprazan, has paved the way for its global availability, including in India, where it is now approved for treating reflux esophagitis and related conditions among adults.
This partnership marks a significant milestone for Sun Pharma in expanding its gastroenterology portfolio and addressing unmet medical needs in the country’s healthcare landscape.
